HARBIN, China, Aug. 10 /PRNewswire-Asia-FirstCall/ -- Weikang
Bio-Technology Group Co., Inc. (OTC Bulletin Board: WKBT) ("Weikang" or the
"Company"), a leading developer, manufacturer and marketer of Traditional
Chinese Medicine (TCM), Western prescription and OTC pharmaceuticals and other
health and nutritional products in the People's Republic of China, today
announced the extension of its foreign invested enterprise business license
(the "FIE Business License") by the Harbin City Administration for Industry
and Commerce.
On November 9, 2007, Sinary became registered as the owner of 100% of Heilongjiang Weikang's registered capital, and was issued the original FIE Business License for Heilongjiang Weikang. The FIE Business License was valid until June 30, 2010. On March 12, 2010, the Harbin City Administration for Industry and Commerce has extended the FIE Business License through November 9, 2027. Additional information can be found in the 8-K the Company filed on August 9, 2010.
"We are very happy to have this administrative issue resolved and to have our business license extended through 2027," commented Mr. Yin Wang, Chairman and CEO of Weikang Bio-Technology Group. "Over the past few years we have made important strides in expanding our business with the acquisition of Tianfang and expansion of our production capacity. With our business license in place, we look forward to continue expanding our market penetration and building a business with long-term, sustainable growth."
About Weikang Bio-Technology Group Co., Inc.
Weikang Bio-Technology Group Co., Inc. is principally engaged in developing, manufacturing and distributing Traditional Chinese Medicine (TCM), and health and nutritional supplements in China, in compliance with requisite Chinese licenses and approvals. The Company is also expanding its business scope to develop, manufacture and distribute Chinese herbal extract products and GMP certified western prescription and OTC pharmaceuticals through its acquisition of Tianfang. For more information, please visit http://www.weikangbio.com .
Safe Harbor Statement
This press release contains certain statements that may include "forward looking statements." All statements other than statements of historical fact included herein are "forward-looking statements." These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.
Advertisement
On November 9, 2007, Sinary became registered as the owner of 100% of Heilongjiang Weikang's registered capital, and was issued the original FIE Business License for Heilongjiang Weikang. The FIE Business License was valid until June 30, 2010. On March 12, 2010, the Harbin City Administration for Industry and Commerce has extended the FIE Business License through November 9, 2027. Additional information can be found in the 8-K the Company filed on August 9, 2010.
Advertisement
"We are very happy to have this administrative issue resolved and to have our business license extended through 2027," commented Mr. Yin Wang, Chairman and CEO of Weikang Bio-Technology Group. "Over the past few years we have made important strides in expanding our business with the acquisition of Tianfang and expansion of our production capacity. With our business license in place, we look forward to continue expanding our market penetration and building a business with long-term, sustainable growth."
About Weikang Bio-Technology Group Co., Inc.
Weikang Bio-Technology Group Co., Inc. is principally engaged in developing, manufacturing and distributing Traditional Chinese Medicine (TCM), and health and nutritional supplements in China, in compliance with requisite Chinese licenses and approvals. The Company is also expanding its business scope to develop, manufacture and distribute Chinese herbal extract products and GMP certified western prescription and OTC pharmaceuticals through its acquisition of Tianfang. For more information, please visit http://www.weikangbio.com .
Safe Harbor Statement
This press release contains certain statements that may include "forward looking statements." All statements other than statements of historical fact included herein are "forward-looking statements." These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.
Company contact:
Ren Hu, VP
Weikang Bio-Technology Group Co., Inc.
US Tel: +1-201-887-0415
China cell: +86-137-1872-8163
Email: [email protected]
Investors Relation contacts:
John Marco, Partner, Elite IR
Tel: +1-310-819-2948
Email: [email protected]
Leslie J. Richardson, Partner, Elite IR
Tel: +852-3183-0283
Email: [email protected]
SOURCE Weikang Bio-Technology Group Co., Inc.